丹参滴丸对急性ST段抬高型心肌梗死PCI术后心肌保护作用

Abstract
Figure/Table
References (28)
Related Citation (13)

Download: PDF (461 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To study the protective effect of Danshen Dripping Pills in patients with ST-segment elevation myocardial infarction (STEMI) after percutaneous coronary intervention (PCI). Methods A total of 109 patients with STEMI in Xianyang Central Hospital of Shaanxi Province from January 2014 to March 2016 were enrolled in this study. The subjects were randomly divided into the control group (54 cases) and the treatment group (55 cases) by the random number table method. All the patients were treated with PCI, and then the control group was treated with Atorvastatin Calcium, the treatment group was treated with Danshen Dripping Pills on basis of the control group. The two groups were treated for 3 months. The levels of serum cardiac troponin I (cTnI), creatine kinase isoenzyme (CK-MB), brain natriuretic peptide (BNP), interleukin 6 (IL-6), C-reactive protein (CRP), tumor necrosis factor-α (TNF-α), nitric oxide (NO), endothelin (ET) and soluble adhesion molecules-1 (sICAM-1) of the two groups before and after treatment were compared and detected. The adverse cardiovascular events of the two groups after discharge for 2 years were compared. Results After treatment, the levels of serum cTnI, CK-MB and BNP of the control group were significantly higher than before treatment, the levels of serum cTnI, CK-MB and BNP of the treatment group were significantly lower than before treatment, and the levels of serum cTnI, CK-MB and BNP of the treatment group were significantly lower than the control group (P ＜ 0.05). After treatment, the levels of serum IL-6, CRP, TNF-α, ET and sICAM-1 of the two groups were significantly lower than before treatment, the serum NO of the two groups was significantly higher than before treatment, and the level changes of serum IL-6, CRP, TNF-α, ET, sICAM-1 and NO in treatment group were better than those of the control group (P ＜ 0.05). There was no significant difference of the rates of adverse cardiovascular events of the two groups during the follow-up period of 2 years (P ＞ 0.05). Conclusion Based on the application of statins, Danshen Dripping Pills in STEMI patients after PCI has strong cardioprotective effect. It can reduce the inflammatory reactions and vascular endothelial injury induced by surgery, with good prognosis, and it is worthy of clinical application.

Key words： ST-segment elevation myocardial infarction Danshen Dripping Pills Percutaneous coronary intervention

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Yi FU Xiaolin LIU Bo TAN Hui LI Kang

Cite this article:

ZHANG Yi FU Xiaolin LIU Bo TAN Hui LI Kang. The myocardial protective effect of Danshen Dripping Pills in patients with ST-segment elevation myocardial infarction after percutaneous coronary intervention[J]. 中国医药导报, 2018, 15(34): 153-156,160.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2018/V15/I34/153

[1] 王刚，王冬梅，丁超.急性ST段抬高型心肌梗死的治疗新进展[J].创伤与急危重病医学，2014，2（1）：26-29.
[2] 刘胜男，包那仁托亚，王文斌，等.老年急性ST段抬高型心肌梗死临床及冠状动脉病变特点分析[J].内蒙古医学杂志，2016，48（12）：1435-1437.
[3] 郭影，赵琳.急性ST段抬高型心肌梗死患者急诊经皮冠状动脉介入治疗术后ST段回落不良的相关因素分析[J].中国卫生标准管理，2017，8（26）：48-49.
[4] 张文娟，张云盛.急性ST段抬高型心肌梗死的介入时机选择[J].天津医药，2017，45（11）：1130-1134.
[5] 李婷婷.药物治疗及急诊PCI治疗急性ST段抬高型心肌梗死的临床效果比较[J].当代医学，2016，22（7）：143-144.
[6] 安杰，温盛燕，佘强.负荷他汀类药物对急性ST段抬高型心肌梗死患者介入治疗术后疗效的Meta分析[J].第三军医大学学报，2017，39（23）：2316-2322.
[7] 贺琳，欧阳泽伟，刘鹏，等.复方丹参滴丸对急性心肌梗死再灌注治疗后氧化应激的影响[J].中国临床研究，2013， 26（6）：531-533.
[8] 沈卫峰，张奇，张瑞岩.2015年急性ST 段抬高型心肌梗死诊断和治疗指南解析[J].国际心血管病杂志，2015，42（4）：217-219.
[9] 辜莹，陶敏，沈小清.ST段抬高型心肌梗死患者急诊PCI转运流程改进[J].护理学杂志，2017，32（19）：51-53.
[10] 卢青，丁世芳，陈志楠，等.瑞舒伐他汀治疗急性ST段抬高型心肌梗死患者经皮冠状动脉介入术后的临床研究[J].中国临床药理学杂志，2017，33（18）：1735-1739.
[11] 韩丽秋，张志，刘紫东.围术期强化他汀治疗对老年ST段抬高型心肌梗死急诊PCI术后近期预后及安全性的影响[J].中国老年学杂志，2017，37（9）：2167-2170.
[12] 邱悦群，钟一鸣.复方丹参滴丸对老年急性心肌梗死急诊冠状动脉介入治疗的影响[J].中国医院用药评价与分析，2007，7（5）：376-377.
[13] 潘洁丽，郏国炯，王萌.中药制剂复方丹参滴丸对急性心肌梗死患者体内核因子-κB p65介导的炎症反应的影响[J].药物生物技术，2017，24（2）：120-123.
[14] 申晓莉.替格瑞洛联合急诊经皮冠状动脉介入治疗对ST段抬高型心肌梗死患者心肌损伤及血小板聚集程度的影响[J].安徽医药，2017，21（10）：1880-1883.
[15] 梁莉莉，张亚男.急性非ST段抬高型心肌梗死患者血清BNP水平与病情及预后的关系[J].山东医药，2016， 56（40）：99-100.
[16] 李广平，郑心田，王怀祯，等.复方丹参滴丸对急性ST段抬高心肌梗死介入治疗的临床作用[J].中国介入心脏病学杂志，2011，19（1）：24-28.
[17] 吴娟，杨朋康，刘文君，等.高敏C反应蛋白预测急性ST段抬高型心肌梗死患者预后的价值[J].实用临床医药杂志，2016，20（7）：178-179.
[18] 曹庭家，王静晖.泮托拉唑在预防心肌梗死患者行经皮冠状动脉支架植入术后消化道出血中的应用[J].现代消化及介入诊疗，2016，21（6）：885-887.
[19] 苏波.盐酸替罗非班不同给药时间对急性ST段抬高型心肌梗死患者的疗效分析[J].中国医药科学，2016，6（2）：47-49.
[20] 方芳，甘受益，冯光瑞，等.长期服用复方丹参滴丸对老年急性心肌梗死患者PCI术后左室重构及炎症因子水平的影响[J].现代生物医学进展，2017，17（3）：544-566.
[21] 吕彬.重组人脑利钠肽对急性心肌梗死老年患者PCI术后心功能及组织灌注的影响[J].中国医药科学，2017，7（24）：226-228，231.
[22] 陈骅，刘昕.重组人脑利钠肽对急性前壁心梗急诊经皮冠状动脉介入术后心室重塑和心功能的影响[J].中国医药导报，2018，15（2）：58-61.
[23] 匡永东，吕良冬.通心络胶囊对急性ST段抬高型心肌梗死患者hs-CRP和ET-1的影响[J].中国现代医生，2011，49（27）：85-86.
[24] 周静，张春艳，马维东，等.急性心肌梗死患者内皮炎症与无复流及冠脉病变严重程度的相关性[J].西安交通大学学报：医学版，2016，37（3）：331-335.
[25] 付莉.急性心肌梗死伴消化道出血患者的临床特征及预后[J].现代消化及介入诊疗，2016，21（1）：11-13.
[26] 王音.急性ST段抬高心肌梗死患者经皮冠脉介入治疗近期预后的危险因素分析[J].中国医药导报，2017，14（23）：44-47.
[27] 李文雯，韦艺丹，魏林林，等.复方丹参滴丸防治急性心肌梗死作用机制的研究进展[J].药学与临床研究，2014， 22（1）：67-71.
[28] 李红宇.丹参滴丸对急性心肌梗死患者血浆BNP及TNF-α水平和心功能的影响研究[J].中国医药指南，2013， 11（25）：17-18.